Get the Daily Brief
Latest Biotech News
Recursion Lays Off 20% Staff Following Pipeline Streamlining
Recursion Pharmaceuticals disclosed a workforce reduction of approximately 20%—about 160 jobs—citing pipeline pruning and challenges in biotech capital markets. The restructuring aims to optimize...
Merck Advances in Cholesterol and RSV Markets Amidst Regulatory Shifts
Merck achieved positive outcomes from two Phase III trials of its oral PCSK9 inhibitor enlicitide decanoate, demonstrating significant LDL cholesterol reductions in hyperlipidemia patients....
NIH Funding Crisis Deepens Amid Staff Protests
More than 300 current and former NIH staff have signed the Bethesda Declaration protesting severe funding cuts and workforce reductions at the National Institutes of Health. Highlighting the...
FDA Halts Gilead's HIV Combo Therapy Trials Amid Safety Concerns
FDA imposed a clinical hold on Gilead Sciences’ multiple trials involving its experimental long-acting HIV combination pills after participants exhibited declines in immune cell counts, raising...
Innovative CAR-T Cells Target Eva1 to Combat Solid Tumors Effectively
Researchers developed a next-generation CAR-T therapy targeting the Eva1 antigen, overcoming historic barriers in treating solid tumors. By engineering enhanced receptor components, the therapy...
Merck’s Oral PCSK9 Inhibitor Cuts LDL in Pivotal Phase III Trials
Merck & Co. announced positive results from two Phase III trials of its oral PCSK9 inhibitor, enlicitide decanoate, showing statistically significant and clinically meaningful reductions in LDL...
NIH Scientists Protest Cuts and Call for Restoration of Biomedical Funding
More than 1,200 NIH researchers signed the Bethesda Declaration, urging reversal of recent funding cuts and workforce reductions seen as politically motivated. The declaration highlights concerns...
Nanotechnology Innovates Fluid Manipulation with Magnetic Microrobots
Scientists at the Chinese Academy of Sciences engineered a magnetic microrobot capable of precise, rapid manipulation of microscopic fluid droplets. This novel device uses a porous, hydrophilic...
Major Funding Granted to Advance Colorectal Cancer Screening Technologies
Tagomics secured £860,000 to enhance its colorectal cancer screening platform via collaboration with NHS research entities. Additionally, a comparative study reveals CT colonography outperforms...
Stem Cell-Based Embryo Models Face Regulatory and Ethical Crossroads
Advancements in stem cell-derived embryo models (SCBEM) offer unprecedented insights into early human development but raise complex regulatory and ethical issues globally. Recent recommendations...
AI Boosts Drug Discovery With Open-Source Model for Binding Affinity Prediction
Scientists at MIT and Recursion Pharmaceuticals launched Boltz-2, an AI-driven open-source platform that predicts small-molecule binding affinities with improved accuracy. This breakthrough...
CAR-T Therapy Targets Novel Solid Tumor Antigen for Enhanced Immunotherapy
Investigators at Nagoya University have engineered a novel CAR-T cell therapy directed against Eva1, a protein overexpressed in various solid tumors including lung, pancreatic, and liver cancers....
Next-Gen Genome Editing Targets Multiple Sites With Precision
Researchers are overcoming limitations in human gene editing by developing advanced tools capable of simultaneously modifying multiple genomic sites with enhanced accuracy. This innovation...
Regulatory Shake-Up: Entire CDC Vaccine Advisory Panel Dismissed
Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP), citing conflicts of interest and intent to...
Metsera Advances Long-Acting Amylin Analog for Obesity Treatment
Metsera has reported encouraging early clinical data for its amylin analog, MET-233i, showing dose-dependent and sustained weight loss with potential for once-monthly dosing. These findings point...
Merck Launches Oral PCSK9 Inhibitor With Positive Phase III Dual Readouts
Merck & Co. announced successful Phase III results for its oral PCSK9 inhibitor, enlicitide decanoate, demonstrating significant reductions in LDL cholesterol across two key trials in patients...
Recursion Cuts 20% Workforce Amid Pipeline Narrowing
Recursion Pharmaceuticals announced layoffs affecting about 20% of its staff following a strategic pipeline cutback and focus on oncology and rare diseases after merging with Exscientia. The...
Predicting Viral Evolution Reveals Broad SARS-CoV-2 Antibodies
A novel computational framework integrating viral evolution modeling and immunology has identified broadly neutralizing antibodies against current and anticipated SARS-CoV-2 variants. This...
Merck’s Oral PCSK9 Inhibitor Clears Hurdle With Phase III Wins
Merck announced positive results from two phase III trials of its oral PCSK9 inhibitor, enlicitide decanoate, demonstrating significant reductions in LDL cholesterol in patients on statins with...
Merck’s Oral PCSK9 Inhibitor and Amylin Obesity Drug Poised For Market Impact
Merck reported promising Phase III data for its oral PCSK9 inhibitor enlicitide decanoate, showing significant LDL cholesterol reductions, aiming to capture a spot in a competitive market....